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monitoring started from 1 July 2001. The primary outcome mea-
surement was the LDL levels. The secondary outcome measure-
ment was the percentage of goal attainment. Lipid control was
deﬁned as adequate if the LDL level was < or = 2.6mmol/L. The
LDL levels were measured at baseline, 1, 3, 6, and 12 months.
RESULTS: A total of 617 patients were recruited. There were
383 patients in the intensive monitoring group and 283 patients
in the control group. In the control group, a less intensive mon-
itoring was adopted. Less than 20% of control group patients
had a regular 3-monthly LDL-levels monitoring. Over 60% of
patients in the intensive monitoring group and 10% of the
control group patients reached target LDL-levels by week 4.
Over 90% of the intensive monitoring group patients maintained
at target LDL levels in a following 6-month period. CONCLU-
SION: This study shows that intensive monitoring of LDL-levels
in hyperlipidaemic patients receiving PCI have a higher goal
attainment rate that remains high within 6-month period. This
study paves way for a prospective, randomized-control trial to
conﬁrm the results in the future.
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OBJECTIVES: To evaluate lipid level changes, NCEP-ATPIII
LDL-C goal attainment and time to goal in a managed care
setting. METHODS: Patients were included if they began ator-
vastatin, ﬂuvastatin, pravastatin, or simvastatin therapy between
July 1, 1999 and June 30, 2001, and had no dyslipidemic therapy
in the previous 6 months, continuous health plan enrollment, 6
months pre-index and 12 months post-index, and post-index
lipid measurements. Goal attainment status was assessed at each
LDL-C lab result utilizing NCEP-ATPIII guidelines. Descriptive
statistics, generalized estimating equations (GEE), and Cox 
proportional hazard with multiple-failure data were employed
for analysis. Model covariates included age, gender, coronary
artery disease, diabetes mellitus, hypertension, duration of statin
therapy, medication possession ratio (MPR), and baseline lipid
proﬁle. RESULTS: A total of 16,979 patients were identiﬁed for
this study (ﬂuvastatin = 1251; pravastatin = 2302; simvastatin =
5603; atorvastatin = 7823). The mean overall age of the cohort
was 62 ± 13 years, 49% were male, and 58% of patients were
deﬁned as secondary prevention by NCEP-ATPIII risk criteria.
The overall mean duration of therapy (persistence) was 16 ± 9
months and adherence to therapy (MPR) was 79%. The
mean/median doses were as follows: atorvastatin = 14mg/10mg,
ﬂuvastatin = 35mg/40mg, pravastatin = 28mg/20mg and sim-
vastatin = 24mg/20mg. Changes in lipid levels for atorvastatin,
ﬂuvastatin, pravastatin, and simvastatin were as follows: total
cholesterol (-21%, -15%, -16%, -20%), LDL-C (-28%, 
-21%, -23%, -28%), HDL-C (0.1%, 1.0%, 1.0%, 1.5%), 
and triglycerides (-8%, -1%, -3%, -5%), respectively. The
probabilities of achieving LDL-C goal and median times to 
goal were: atorvastatin (0.51, 236 days); ﬂuvastatin (0.30, 379
days); pravastatin (0.35, 377 days); simvastatin (0.47, 246 
days). CONCLUSIONS: Patients who were prescribed atorvas-
tatin had signiﬁcantly greater improvements in total cholesterol
and triglycerides and attained LDL-C goal signiﬁcantly more
often evaluating each lab result independently. Changes in 
LDL-C and HDL-C were similar between atorvastatin and 
simvastatin.
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OBJECTIVE: Angiotension II receptor antagonists (ARB)
provide a new therapeutic option for hypertensive patients. This
analysis examines patient utilization patterns subsequent to ini-
tiation on an ARBs. METHODS: This study uses a retrospective
cohort design with a six-month baseline period and a twelve-
month evaluation period. New users of ARBs were identiﬁed in
AdvancePCS¢ pharmacy claims database. Studied patients were
continuously eligible for pharmacy beneﬁts, 20 to 80 years of
age, and initiated therapy on losartan, valsartan, ibersartan, can-
desartan, telmisartan, losartan HCT, valsartan HCT, candesar-
tan HCT, or telmisartan HCT between November 1, 2001 and
April 30, 2002. RESULTS: A total of 167,083 patients initiated
ARB therapy during the enrollment window, 72% on ARB
monotherapy and 28% on combination therapy. Monotherapy
patients (p < 0.05) were more likely to discontinue than combi-
nation therapy patients. No other signiﬁcant differences in 
discontinuation rates were identiﬁed. Patients who initiated with
monotherapy were equally likely to add a diuretic as a second
therapy regardless of ARB. Patients who initiated on telmisartan
were less likely (p < 0.05) than patients who initiated on losar-
tan (OR = 0.67), valsartan (OR = 0.81), ibersartan (OR = 0.82),
or candesartan (OR = 0.82) to receive triple anti-hypertensive
therapy. Similarly, patients who initiated on valsartan (OR =
1.23) or losartan monotherapy (OR = 1.14) were more likely
than other monotherapy patients (p < 0.05) to titrate upwards.
Combination patients who initiated on losartan HCT or valsar-
tan HCT were more likely to add another anti-hypertensive drug
than were patients who initiated on either candesartan HCT (OR
= 0.69, p < 0.05) or telmisartan HCT (OR = 0.82, p < 0.05).
Those who initiated telmisartan HCT were least likely to
increase the initial dose (p < 0.05). CONCLUSIONS: Differences
in patient utilization patterns were identiﬁed based on initial
choice of ARB. These ﬁndings may result from differential clin-
ical efﬁcacy, patient health history, or managed care inﬂuence on
drug choice.
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OBJECTIVES: Carotid artery stenosis is an important risk factor
for, and is also believed to cause as much as 20% all strokes.
Several surgical therapies are available including carotid
endarterectomy (CEA) and carotid angioplasty with stenting
(CAS). Although there appear to be beneﬁts to adopting wide-
spread use of CAS, numerous parties have expressed concern
about its safety. A number of large protected CAS (PCAS) trials
are underway, however, it will be 3 to 5 years until these results
are released. In the interim, PCAS continues to be employed.
Since numerous PCAS studies were recently published, the aim
of this systematic review was to answer the question: based on
the most recent evidence, what is the efﬁcacy of protected carotid
angioplasty with stenting (PCAS)? METHODS: Electronic,
manual and bibliographic searches of Medline, PreMedline,
Healthstar/OVID, EMBase, PubMed were conducted.
RESULTS: Over 400 articles were identiﬁed, of which 18 studies
met the inclusion criteria. The technical complication rate of
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PCAS was 3.3%, the overall adverse event rate was 3.1% and
the 30-day mortality rate was 1.2%. A chi-square analysis of the
adverse event rates revealed no clear relationship between the
study group and proportion of adverse events among all 18
studies (¥2 = 14.6, p > 0.10). Multiple sensitivity analyses were
conducted; however, no relationship between the study group
and proportion of adverse events resulted (¥2 = 11.2, p > 0.10).
CONCLUSION: Although practitioners await stronger evi-
dence, this study demonstrates the relatively low rates of adverse
events in PCAS relative to CAS alone and the warranted use of
PCAS.
PCV14
A COMPARISON OF THE RISK OF ADVERSE
THROMBOEMBOLIC AND BLEEDING EVENTS BETWEEN
SUBJECTS TREATED AND NOT TREATED WITH WARFARIN
Riedel A1, Hauch O2, Harley C1, Nelson M1,Wygant G2,
Reynolds MW2
1Ingenix, Eden Prairie, MN, USA; 2AstraZeneca, L.P, Wilmington, DE,
USA
OBJECTIVE: This study was conducted to assess the risk of
thromboembolic and bleeding events among atrial ﬁbrillation
patients treated with warfarin. METHODS: Using claims data
from a large commercial health plan, patients with chronic atrial
ﬁbrillation were identiﬁed based on medical claims with diag-
nosis codes 427.31 and 427.32 from 1998 through 1999.
Patients with valvular disease were excluded. Cox proportional
hazards analysis was used to compare risk of venous, arterial,
intracranial, and total thromboembolic events between warfarin
exposed and unexposed subjects. Risk of bleeding events was
also compared. RESULTS: A total of 6764 subjects were retained
for analysis; of these 3541 (52.4%) were exposed to warfarin
during the follow-up period. Among thromboembolic events,
treated subjects were signiﬁcantly less likely to experience arter-
ial events compared to non-treated subjects (HR: 0.710, CI:
0.540–0.934). No differences in the risk of venous or intracra-
nial events were found, nor in the risk of thromboembolic events
overall. Use of warfarin signiﬁcantly increased the risk of minor
bleeding events (HR: 3.600, CI: 2.537–5.109), and all bleeding
events (HR: 1.502, CI: 1.289–1.749). CONCLUSIONS: A large
number of atrial ﬁbrillation patients are not being treated with
warfarin. After adjusting for baseline characteristics, the risk of
thromboembolic events in this population was not signiﬁcantly
different between those exposed and unexposed to warfarin.
There was a signiﬁcant increase in the risk for minor and total
bleeding events among patients treated with warfarin. Both
observational studies and decision analytic models have indi-
cated that the outcomes of warfarin therapy is highly dependent
of how it is managed. The present study seems to indicate that
there is a signiﬁcant gap between the performance of warfarin
in reducing the risk of thromboembolic events as shown in
tightly controlled clinical trials or coagulation clinics versus what
is achievable in general practice.
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OBJECTIVES: Diabetic patients have a higher risk of coronary
artery disease. Percutaneous coronary intervention (PCI) with
stenting has become the standard of care to repair coronary
vessel blockage. However, stenting increases the risk of throm-
bus formation at the implantation site. Platelet glycoprotein
IIb/IIIa antagonist drugs reduce this risk. This study examines
whether abciximab and eptiﬁbatide are cost-effective as adjunct
therapies in diabetic patients undergoing PCI with stenting.
METHODS: Included were diabetic patients undergoing elective
or urgent PCI with stenting. Clinical outcome data was extracted
from the published EPISTENT and ESPRIT trials. Abciximab (N
= 335) and eptiﬁbatide (N = 419), with stenting, were compared
to a treatment group of stent-only patients. Short-term (one year)
and long-term (survival-Markov model) decision analytic models
(DATA 4.0) were constructed from a Canadian provincial health
system perspective. Results are reported in 2001 Canadian
dollars and presented on a per person basis. A 5% discount rate
was used. Probabilistic sensitivity analysis (SA) was done using
Crystal Ball. RESULTS: For abciximab + stent, incremental costs
were higher (+$81) but clinical outcomes were better (-18.5%
major adverse cardiac events [MACE] and -3% mortality) rela-
tive to the stent-only group. The incremental cost-effectiveness
ratio for abciximab was $438 per MACE avoided and $2700
per death avoided. Abciximab + stent patients had 0.22 more
adjusted life years (LYs) than the stent-only group so the incre-
mental ratio was $368 per adjusted LYs gained. When compared
to the stent-only group, eptiﬁbatide + stent was dominant in
terms of costs (Incremental = $166), MACE rate (Incremental =
7.1%) and mortality (Incremental = 2%) over the short-term.
There was a 0.22LY increase for eptiﬁbatide. SA indicated that
drug acquisition and procedure costs were the major cost drivers.
Results were robust. CONCLUSIONS: Eptiﬁbatide and abcix-
imab (+stenting) are considered cost-effective in the treatment of
diabetic patients undergoing PCI.
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OBJECTIVES: The economic consequences of heart failure (HF)
in post-myocardial infarction (MI) patients can be severe.
Recently there has been an increase in the availability of drugs
aimed at treating or delaying the onset of post-MI HF. The objec-
tive of this study was to estimate differences in costs, number of
hospitalizations and outpatient visits in post-MI patients with
and without HF. METHODS: Claims data for patients hospi-
talized with a principal diagnosis of MI between 1998 and 2000
were used. Patients with a diagnosis of HF or MI in the six-
months preceding the initial MI were excluded. Data on 13,682
patients for a period of 3-years following discharge for initial MI
was available. The follow-up period was divided into 18 two-
month intervals. Mean costs were analyzed using a two-part
model (logistic and generalized linear model (GLM)), and out-
patient visits and hospitalizations were analyzed using a GLM
model with log-link. Clustering of observations within patients
was adjusted for, and bootstrapping was used to obtain standard
errors. Age, gender, type of MI, insurance type, and comorbidi-
